University of Miami Sylvester Comprehensive Cancer Center
Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Checkpoint Inhibitor Targeting CD47 in R/R AML
Comments 0
Login to view comments.
Click here to Login
